All In Biotech

Drug Trial Radar · NCT06011291

A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYH2051 Monotherapy in Patients With Advanced Solid Tumors or in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer

Last checked: Nov 20, 2026Latest source record: Oct 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

73

Planned (sponsor's estimate)

Start

Aug 15, 2023

Primary completion

Dec 31, 2024

Study completion Aug 31, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with radiotherapy (RT) in patients with locally advanced head and neck cancer.

Conditions

  • Solid Tumors
  • Head and Neck Cancer

Interventions

  • SYH2051 tabletsDrug

    Arm A: Five dose levels will be administered sequentially. Arm B and C: Concurrently administered with RT, and 2 weeks adjuvant treatment after RT.

  • Intensity-Modulated Radiation Therapy (IMRT)Radiation

    Radical or adjuvant radiotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs)Time frame: 31 days for Arm A and 11 weeks for Arm B
  2. Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: 2 years
  3. Maximum tolerated dose (MTD)(if any) or maximum administrated dose (MAD)Time frame: up to 1 year
  4. Recommended phase 2 dose (RP2D) of SYH2051 in combination with RTTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials Information Group

    Shijiazhuang, Hebei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.